Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
Metoject® Subcutaneous Injection Pen Approved in Japan for methotrexate Treatment
Details : Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.
Brand Name : Metoject
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2024
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : Eisai
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?